242 related articles for article (PubMed ID: 18716861)
21. The long and winding road: From mouse linkage studies to a novel human therapeutic pathway in type 1 diabetes.
Rojas M; Heuer LS; Zhang W; Chen YG; Ridgway WM
Front Immunol; 2022; 13():918837. PubMed ID: 35935980
[TBL] [Abstract][Full Text] [Related]
22. Type 1 diabetes vaccine candidates promote human Foxp3(+)Treg induction in humanized mice.
Serr I; Fürst RW; Achenbach P; Scherm MG; Gökmen F; Haupt F; Sedlmeier EM; Knopff A; Shultz L; Willis RA; Ziegler AG; Daniel C
Nat Commun; 2016 Mar; 7():10991. PubMed ID: 26975663
[TBL] [Abstract][Full Text] [Related]
23. Th1-Like ICOS+ Foxp3+ Treg Cells Preferentially Express CXCR3 and Home to β-Islets during Pre-Diabetes in BDC2.5 NOD Mice.
Kornete M; Mason ES; Girouard J; Lafferty EI; Qureshi S; Piccirillo CA
PLoS One; 2015; 10(5):e0126311. PubMed ID: 25946021
[TBL] [Abstract][Full Text] [Related]
24. Revealing the specificity of regulatory T cells in murine autoimmune diabetes.
Spence A; Purtha W; Tam J; Dong S; Kim Y; Ju CH; Sterling T; Nakayama M; Robinson WH; Bluestone JA; Anderson MS; Tang Q
Proc Natl Acad Sci U S A; 2018 May; 115(20):5265-5270. PubMed ID: 29712852
[TBL] [Abstract][Full Text] [Related]
25. B7-2 (CD86) controls the priming of autoreactive CD4 T cell response against pancreatic islets.
Yadav D; Judkowski V; Flodstrom-Tullberg M; Sterling L; Redmond WL; Sherman L; Sarvetnick N
J Immunol; 2004 Sep; 173(6):3631-9. PubMed ID: 15356107
[TBL] [Abstract][Full Text] [Related]
26. KLRG1 expression identifies short-lived Foxp3
Kornete M; Mason E; Istomine R; Piccirillo CA
Autoimmunity; 2017 Sep; 50(6):354-362. PubMed ID: 28850267
[TBL] [Abstract][Full Text] [Related]
27. Preventative role of interleukin-17 producing regulatory T helper type 17 (Treg 17) cells in type 1 diabetes in non-obese diabetic mice.
Bellemore SM; Nikoopour E; Schwartz JA; Krougly O; Lee-Chan E; Singh B
Clin Exp Immunol; 2015 Dec; 182(3):261-9. PubMed ID: 26250153
[TBL] [Abstract][Full Text] [Related]
28. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes.
Kadri N; Korpos E; Gupta S; Briet C; Löfbom L; Yagita H; Lehuen A; Boitard C; Holmberg D; Sorokin L; Cardell SL
J Immunol; 2012 Apr; 188(7):3138-49. PubMed ID: 22371394
[TBL] [Abstract][Full Text] [Related]
29. Dynamics of pathogenic and suppressor T cells in autoimmune diabetes development.
Gregori S; Giarratana N; Smiroldo S; Adorini L
J Immunol; 2003 Oct; 171(8):4040-7. PubMed ID: 14530324
[TBL] [Abstract][Full Text] [Related]
30. Protection from type 1 diabetes by invariant NK T cells requires the activity of CD4+CD25+ regulatory T cells.
Ly D; Mi QS; Hussain S; Delovitch TL
J Immunol; 2006 Sep; 177(6):3695-704. PubMed ID: 16951329
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast Cell-Based Therapy for Experimental Autoimmune Diabetes.
Jalili RB; Zhang Y; Hosseini-Tabatabaei A; Kilani RT; Khosravi Maharlooei M; Li Y; Salimi Elizei S; Warnock GL; Ghahary A
PLoS One; 2016; 11(1):e0146970. PubMed ID: 26765526
[TBL] [Abstract][Full Text] [Related]
32. PTPN22 controls virally-induced autoimmune diabetes by modulating cytotoxic T lymphocyte responses in an epitope-specific manner.
Fousteri G; Jofra T; Di Fonte R; Kuka M; Iannacone M; Battaglia M
Clin Immunol; 2015 Feb; 156(2):98-108. PubMed ID: 25513733
[TBL] [Abstract][Full Text] [Related]
33. Are Regulatory T Cells Defective in Type 1 Diabetes and Can We Fix Them?
Visperas A; Vignali DA
J Immunol; 2016 Nov; 197(10):3762-3770. PubMed ID: 27815439
[TBL] [Abstract][Full Text] [Related]
34. Genetic and therapeutic control of diabetogenic CD8+ T cells.
Santamaria P
Novartis Found Symp; 2008; 292():130-6; discussion 136-45, 202-3. PubMed ID: 19209463
[TBL] [Abstract][Full Text] [Related]
35. Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model.
Holohan DR; Van Gool F; Bluestone JA
PLoS One; 2019; 14(10):e0217728. PubMed ID: 31647813
[TBL] [Abstract][Full Text] [Related]
36. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in prevention of autoimmune diabetes in non-obese diabetic mice treated with alpha-galactosylceramide.
Li W; Ji F; Zhang Y; Wang Y; Yang N; Ge H; Wang F
Acta Biochim Biophys Sin (Shanghai); 2008 May; 40(5):381-90. PubMed ID: 18465023
[TBL] [Abstract][Full Text] [Related]
37. Constitutively active Stat5b signaling confers tolerogenic functions to dendritic cells of NOD mice and halts diabetes progression.
Zerif E; Maalem A; Gaudreau S; Guindi C; Ramzan M; Véroneau S; Gris D; Stankova J; Rola-Pleszczynski M; Mourad W; Dupuis G; Amrani A
J Autoimmun; 2017 Jan; 76():63-74. PubMed ID: 27634616
[TBL] [Abstract][Full Text] [Related]
38. Type 1 diabetes and T regulatory cells.
ElEssawy B; Li XC
Pharmacol Res; 2015 Aug; 98():22-30. PubMed ID: 25959211
[TBL] [Abstract][Full Text] [Related]
39. Differences in T regulatory cells between mouse strains frequently used in immunological research: Treg cell quantities and subpopulations in NOD, B6 and BALB/c mice.
Godoy GJ; Paira DA; Olivera C; Breser ML; Sanchez LR; Motrich RD; Rivero VE
Immunol Lett; 2020 Jul; 223():17-25. PubMed ID: 32330480
[TBL] [Abstract][Full Text] [Related]
40. Antigen-Specific Treg Therapy in Type 1 Diabetes - Challenges and Opportunities.
Serr I; Drost F; Schubert B; Daniel C
Front Immunol; 2021; 12():712870. PubMed ID: 34367177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
